Hormone replacement therapy and estrogen-dependent cancers

Area of Science:

• Gynecology
• Oncology
• Endocrinology

Background:

• Historically, breast cancer treatment contra-indicated hormone replacement therapy (HRT).
• Increased survival rates for early-stage breast cancer lead to more postmenopausal women seeking treatment for severe vasomotor symptoms.
• These survivors also express concerns about postmenopausal osteoporosis and cardiovascular disease risks.

Purpose of the Study:

• To outline a differentiated approach to HRT in breast cancer survivors.
• To address the management of menopausal symptoms and associated health risks in this population.

Main Methods:

• Differentiated HRT approach based on cancer staging, estrogen-receptor (ER) status, and lymph-node metastasis.
• Consideration of continuous combined HRT for ER-negative patients.
• Use of nonaromatizable progestins (e.g., medroxyprogesterone acetate) for ER-positive, lymph-node-negative patients, potentially transitioning to combined HRT after cancer stabilization.
• Addition of MPA for symptomatic ER-positive, lymph-node-positive patients on tamoxifen, who already benefit from osteoporosis and cardiovascular protection.

Main Results:

• No contraindication for HRT in ER-negative breast cancer survivors.
• Progestin therapy is a viable option for symptom relief in ER-positive, lymph-node-negative patients.
• Tamoxifen therapy offers protective benefits against osteoporosis and cardiovascular disease in ER-positive, lymph-node-positive patients.

Conclusions:

• HRT can be considered in select breast cancer survivors based on individualized risk assessment.
• Careful consideration of cancer characteristics and patient consent is crucial.
• Balancing quality of life with life prolongation presents an evolving ethical challenge.